Hartford Investment Management Co. Sells 1,460 Shares of Edwards Lifesciences Co. (NYSE:EW)

Hartford Investment Management Co. decreased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 3.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 36,439 shares of the medical research company’s stock after selling 1,460 shares during the period. Hartford Investment Management Co.’s holdings in Edwards Lifesciences were worth $2,698,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of EW. Alpha Financial Partners LLC bought a new position in shares of Edwards Lifesciences in the 3rd quarter valued at $693,000. Koshinski Asset Management Inc. acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at $396,000. Vontobel Holding Ltd. boosted its holdings in shares of Edwards Lifesciences by 5.7% during the 3rd quarter. Vontobel Holding Ltd. now owns 439,106 shares of the medical research company’s stock valued at $28,977,000 after acquiring an additional 23,560 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at $792,000. Finally, Trust Co. of Vermont boosted its holdings in shares of Edwards Lifesciences by 36.1% during the 3rd quarter. Trust Co. of Vermont now owns 3,019 shares of the medical research company’s stock valued at $199,000 after acquiring an additional 801 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on EW. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their price objective for the company from $82.00 to $90.00 in a report on Monday, December 16th. Wolfe Research downgraded Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective on the stock. in a report on Thursday, January 16th. Citigroup raised their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Daiwa America downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. Finally, Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus price target of $79.71.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the sale, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. This represents a 2.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $75.83 on Thursday. The firm has a market capitalization of $44.72 billion, a P/E ratio of 10.94, a P/E/G ratio of 3.64 and a beta of 1.10. The firm’s 50-day moving average price is $72.47 and its 200-day moving average price is $69.32. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.